Roche’s star multiple sclerosis (MS) drug Ocrevus (ocrelizumab) infusion has been approved in Europe, the first and only approved disease-modifying drug for a debilitating form of the disease. EU ...
Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS) has not ...
– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...
Roche Holding AG (OTCQX:RHHBY, OTCPK:RHHVF, OTCQX:RHHBF) is a good long-term biotech to own. That's because it already has received FDA approval for its multiple sclerosis [MS] drug OCREVUS. This drug ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 4 th ...
Roche’s multiple sclerosis superstar Ocrevus has run into few obstacles on its path to nearly $1 billion in global sales this year. Now, one major obstacle on the drug's blockbuster journey—England's ...
Multiple sclerosis is an inflammatory autoimmune disease, meaning the body attacks itself. The damage plays out in the central nervous system (brain and spinal cord), where the nerve endings and the ...
New analyses highlight the need for active treatment in underrepresented populations, such as primary progressive MS (PPMS) patients with more advanced disability and relapsing MS (RMS) patients of ...
The U.S. Food and Drug Administration (FDA) approved Roche Holding AG’s multiple sclerosis (MS) drug Ocrevus Tuesday, making it the first U.S.-approved medicine for the primary progressive form of the ...
Roche’s much-anticipated multiple sclerosis drug ocrelizumab trounced a standard treatment, Rebif, in a new analysis of Phase III data, adding to competitive stats that could prove an edge in the ...
The Food and Drug Administration approved a new drug to treat multiple sclerosis Tuesday. The drug, called Ocrevus, is approved for use against the most common form of MS – the relapsing-remitting ...
Roche’s star multiple sclerosis (MS) drug Ocrevus (ocrelizumab) infusion has been approved in Europe, the first and only approved disease-modifying drug for a debilitating form of the disease. EU ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback